Is Pfizer Stock a Buy Ahead of This Highly Anticipated Weight Loss Readout?

Motley Fool2023-11-27

Pfizer's stock performance has been disappointing this year (down 38%). The company has faced multiple challenges, such as declining revenues from COVID-19 products, looming patent cliffs for key ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2386929036?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-11-27 18:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2386929036","market":"us","top_or_hot":-1,"title":"Is Pfizer Stock a Buy Ahead of This Highly Anticipated Weight Loss Readout?","media":"Motley Fool","content":"<div>\n<p>Pfizer's stock performance has been disappointing this year (down 38%). The company has faced multiple challenges, such as declining revenues from COVID-19 products, looming patent cliffs for key ...</p>\n\n<a href=\"https://www.fool.com/investing/2023/11/26/is-pfizer-stock-a-buy-ahead-of-this-highly-anticip/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Pfizer Stock a Buy Ahead of This Highly Anticipated Weight Loss Readout?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Pfizer Stock a Buy Ahead of This Highly Anticipated Weight Loss Readout?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-11-27 18:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2023/11/26/is-pfizer-stock-a-buy-ahead-of-this-highly-anticip/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer's stock performance has been disappointing this year (down 38%). The company has faced multiple challenges, such as declining revenues from COVID-19 products, looming patent cliffs for key ...</p>\n\n<a href=\"https://www.fool.com/investing/2023/11/26/is-pfizer-stock-a-buy-ahead-of-this-highly-anticip/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999001176.USD","symbol_name":"United Global Healthcare Acc USD","start_time":0,"source_url":"https://www.fool.com/investing/2023/11/26/is-pfizer-stock-a-buy-ahead-of-this-highly-anticip/","article_id":"2386929036","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2386929036","pubTimestamp":1701080675,"columns":[],"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"An upcoming mid-stage readout may not spark a trend reversal in the big pharma's shares.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999001176.USD":"United Global Healthcare Acc USD","PFE":"辉瑞","BK4592":"伊斯兰概念","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","BK4534":"瑞士信贷持仓","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","BK4585":"ETF&股票定投概念","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BK4007":"制药","BK4581":"高盛持仓","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","BK4550":"红杉资本持仓","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","BK4588":"碎股","BK4568":"美国抗疫概念","LU0234572021.USD":"高盛美国核心股票组合Acc","SG9999002232.USD":"Allianz Global High Payout USD","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0058720904.USD":"联博国际健康护理基金A","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC"},"translate_title":"在这个备受期待的减肥数据公布之前，辉瑞的股票值得买入吗？","themeId":"c5bbfdf5f7964880af97c1d6f417052c","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":1},"content_text":"Pfizer's stock performance has been disappointing this year (down 38%). The company has faced multiple challenges, such as declining revenues from COVID-19 products, looming patent cliffs for key drugs like Eliquis later this decade, and strategic uncertainties for some of its more recent acquisitions.For example, Pfizer bought Global Blood Therapeutics and Arena Pharmaceuticals to expand its portfolio in rare blood and autoimmune diseases, respectively. However, these assets are not without competition, and their long-term potential may be limited by rivals with potentially superior clinical profiles.Still, Pfizer's stock isn't without its merits. The company's shares are presently trading at a near-historic low from a forward-looking price-to-earnings standpoint, and its annualized dividend yield has swelled to a breathtaking 5.37% in 2023.What's more, Pfizer is nearing a highly anticipated phase 2b trial readout for its orally administered, glucagon-like peptide-1 receptor agonist (GLP-1-RA) danuglipron in obese adults. Results from the trial, along with Pfizer's decision on its future development, are both due out before year's end.Is this clinical readout a buying opportunity?Even as a follow-on therapy to first movers like Novo Nordisk's Wegovy and Eli Lilly's Zepbound, Pfizer's oral GLP-1-RA could eclipse the $5 billion sales mark, according to some estimates. The core reason is the sheer girth of the global weight loss market. Estimates vary, but most analysts expect the weight loss drug market to surpass the $100 billion mark by 2033.Novo Nordisk and Eli Lilly are generally expected to capture around 80% of this market by the end of the decade, with the remaining share being divvied up by a handful of late-comers. The leftovers in this case, however, should be substantial, comprising a market that's likely to top $20 billion on the conservative end. More optimistic takes put this figure closer to $40 billion at the mid-decade mark in the 2030s.So, in theory, a positive readout for danuglipron that leads to the launch of a late-stage trial ought to be a major catalyst for the drugmaker's stock. While this thesis seems logical, there are some complicating factors that could lead to a muted response by the market.Chief among them is the fact that these forthcoming data will be for the drug's twice-daily dosing regimen. A twice-daily oral tablet probably won't be particularly competitive in the back half of the decade based on the direction the field is moving.To address this all-important issue, Pfizer is developing a once-daily, modified-release version of danuglipron. However, the company seems to be waiting on additional data before deciding on next steps.Meanwhile, Lilly is moving forward with its next-generation weight loss therapy retatrutide. If Lilly's triple hormone receptor agonist hits the mark in late-stage testing, Pfizer and other late-comers to the field may have a tough time capturing market share. After all, the clinical data thus far indicate that retatrutide could be a game-changer for not only obesity but other conditions like fatty liver disease that are closely associated with being overweight.Key takeawayPfizer's stock probably won't get a sustained boost from these upcoming mid-stage data due to the rapidly evolving competitive landscape for weight loss medications. That's not to say the big pharma's shares aren't worth owning, but prospective buyers may want to base their decision on other factors such as the company's bargain basement valuation, above-average dividend yield, or its broader pipeline.","kind":"highlight","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2386929036"}